Literature DB >> 12745762

Cost of dementia: impact of disease progression estimated in longitudinal data.

Christian Kronborg Andersen1, Jørgen Lauridsen, Kjeld Andersen, Per Kragh-Sørensen.   

Abstract

AIMS: Several studies have shown that health care costs are higher for demented than for non-demented persons and that health care costs are higher for more severe demented persons than less severe demented persons. However, most studies report on cross-sectional study designs, and thus fail to examine the influence of disease progression on changes in health care costs to individual persons. The objective of this study was, using longitudinal data, to examine changes in total health care costs with disease progression in demented persons.
METHODS: We assumed that disease progression could be characterised by transitions between different states of dementia which reflected the degree to which the disease progressed over time. Then, changes in health care costs were regressed on a set of explanatory variables including disease progression. A total of 465 demented and non-demented persons were interviewed twice. The time between interviews was about three years. Before each interview, the participant was examined for dementia and classified by type of dementia (Alzheimer's disease, vascular or other types of dementia) and degree of dementia (very mild, mild, moderate, severe).
RESULTS: The results of this longitudinal study confirmed that health care costs increased over time for non-demented as well as for demented persons and that health care costs increased with disease progression. In particular, the health care costs increased when the disease had progressed into the severe state of the dementia. Also, decline in functional abilities was an important factor for explaining changes in health care costs.

Entities:  

Mesh:

Year:  2003        PMID: 12745762     DOI: 10.1080/14034940210134059

Source DB:  PubMed          Journal:  Scand J Public Health        ISSN: 1403-4948            Impact factor:   3.021


  20 in total

Review 1.  Alzheimer's disease: the strength of association of costs with different measures of disease severity.

Authors:  J Mauskopf; J Racketa; E Sherrill
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Smoking cessation and Alzheimer's disease: facts, fallacies and promise.

Authors:  Janine K Cataldo; Stanton A Glantz
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Cost-of-illness studies based on massive data: a prevalence-based, top-down regression approach.

Authors:  Björn Stollenwerk; Thomas Welchowski; Matthias Vogl; Stephanie Stock
Journal:  Eur J Health Econ       Date:  2015-02-04

Review 5.  Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

6.  Closer caregiver and care-recipient relationships predict lower informal costs of dementia care: The Cache County Dementia Progression Study.

Authors:  Gail B Rattinger; Elizabeth B Fauth; Stephanie Behrens; Chelsea Sanders; Sarah Schwartz; Maria C Norton; Chris Corcoran; C Daniel Mullins; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Alzheimers Dement       Date:  2016-04-18       Impact factor: 21.566

Review 7.  Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.

Authors:  Roy W Jones; Paul McCrone; Chantal Guilhaume
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  The cost of dementia in Europe: a review of the evidence, and methodological considerations.

Authors:  Linus Jönsson; Anders Wimo
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 10.  Economic considerations in the management of Alzheimer's disease.

Authors:  Carolyn W Zhu; Mary Sano
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.